Monsanto Executives Seek to Reassure Investors Amid Backlash Over Merger

Strategic Insights -

Monsanto's stock experienced a significant surge following meetings between executives and Wall Street investors, with the company's share price rising by 9% to close at $38.44. This uptick followed a series of interviews between executives of Monsanto and Pharmacia, the companies' respective CEOs, and senior officials, during which they outlined projected earnings and growth prospects for the merged entity. According to statements from executives, the combined company is expected to generate earnings between $1.55 and $1.62 per share this year, a more than 50% increase from Monsanto's estimated earnings last year.

Key Takeaways:

  • The merger between Monsanto and Pharmacia has been met with a mixed reaction on Wall Street, with investors initially expressing disappointment over the lack of a premium price for shareholders.
  • Executives from both companies have sought to reassure investors by outlining projected earnings growth and emphasizing the potential for the merged entity to drive innovation in the agricultural biotechnology sector.
  • However, concerns have been raised over Monsanto's agricultural business, which is unpopular among some investors due to the current slump in U.S. agriculture and growing protests against biotechnology.
  • Pharmacia CEO Fred Hassan's comments potentially distancing his company from Monsanto's agricultural business may have contributed to investors' anxieties.
  • Despite the challenges facing the agricultural sector, analysts remain optimistic about Monsanto's long-term prospects, citing the company's ability to grow sales and earnings in a difficult environment.

Statistics:

  • Monsanto's stock price rose by $3.19, or 9%, to close at $38.44 on Tuesday.
  • Pharmacia's stock price rose by $1.81 to $48.81, its highest closing price since the merger was announced.
  • The merged company is expected to generate earnings between $1.55 and $1.62 per share this year.
  • Analysts surveyed by Zacks Investment Research had been expecting standalone Monsanto to earn about $1.24 per share this year.
  • Earnings growth projections indicate a potential 20% annual increase starting from next year.

Sources:

  • Wall Street Journal
  • Reuters
  • Financial Times of London
  • Zacks Investment Research
  • A.G. Edwards & Sons Inc.